Better Therapeutics 

Better Therapeutics, Inc. specializes in creating innovative software-driven prescription digital therapeutics (PDTs) platforms, primarily for the U.S. market. These advanced therapies are developed to manage and treat various cardiometabolic ailments, such as diabetes and heart disease. Their flagship investigational product, BT-001, is a PDT platform that employs digitally delivered Nutritional Cognitive Behavioral Therapy (NCBT) to address type 2 diabetes. The company's development pipeline further includes BT-002, a PDT designed to assist patients with hypertension in controlling their blood pressure, and BT-003, another PDT focused on helping individuals with hyperlipidemia optimize their cholesterol levels. Established in 2015, Better Therapeutics, Inc. operates from its headquarters in San Francisco, California.